Curis (CRIS) E10: $-21.38 (As of Mar. 2026)


CRIS Curis Inc CRIS
54 GF Score
Price $0.31
GF Value $1.04
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Curis E10?

Curis CRIS +60.42% 54 E10 is $-21.38 as of Mar. 2026. GuruFocus rates CRIS with a GF Score™ of 54/100 and a GF Value™ of $1.04 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Curis's adjusted earnings per share data for the three months ended in Mar. 2026 was $-1.250. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-21.38 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 9.20% per year. During the past 5 years, the average E10 Growth Rate was 3.40% per year. During the past 10 years, the average E10 Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Curis was 37.10% per year. The lowest was -11.00% per year. And the median was -2.60% per year.

As of today (2026-06-29), Curis's current stock price is $0.3138. Curis's E10 for the quarter that ended in Mar. 2026 was $-21.38. Curis's Shiller PE Ratio of today is .


Curis  (NAS:CRIS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Curis E10 Related Terms


Curis E10 Historical Data

* Premium members only.

The historical data trend for Curis's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis E10 Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.64 -29.14 -29.05 -27.80 -21.81

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.23 -23.69 -23.36 -21.81 -21.38

CRIS vs CALC, ICU, TRAW: E10 Comparison

For the Biotechnology subindustry, Curis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Shiller PE Ratio falls into.


CRIS
54GF Score
Curis Inc CRIS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Curis's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.25/330.2130*330.2130
=-1.250

Current CPI (Mar. 2026) = 330.2130.

Curis Quarterly Data

per share eps CPI Adj_EPS
201606 -9.000 241.018 -12.331
201609 -21.000 241.428 -28.723
201612 -8.000 241.432 -10.942
201703 -11.000 243.801 -14.899
201706 -9.800 244.955 -13.211
201709 -10.600 246.819 -14.181
201712 -4.400 246.524 -5.894
201803 -6.600 249.554 -8.733
201806 -5.200 251.989 -6.814
201809 -4.400 252.439 -5.756
201812 -3.600 251.233 -4.732
201903 -6.000 254.202 -7.794
201906 -4.400 256.143 -5.672
201909 -3.800 256.759 -4.887
201912 -5.200 256.974 -6.682
202003 -5.600 258.115 -7.164
202006 -3.400 257.797 -4.355
202009 -2.200 260.280 -2.791
202012 -2.200 260.474 -2.789
202103 -2.200 264.877 -2.743
202106 -2.400 271.696 -2.917
202109 -2.400 274.310 -2.889
202112 -3.000 278.802 -3.553
202203 -3.600 287.504 -4.135
202206 -3.400 296.311 -3.789
202209 -2.830 296.808 -3.149
202212 -2.400 296.797 -2.670
202303 -2.390 301.836 -2.615
202306 -2.470 305.109 -2.673
202309 -2.130 307.789 -2.285
202312 -2.030 306.746 -2.185
202403 -2.050 312.332 -2.167
202406 -2.030 314.175 -2.134
202409 -1.700 315.301 -1.780
202412 -1.250 315.605 -1.308
202503 -1.250 319.799 -1.291
202506 -0.680 322.561 -0.696
202509 -0.490 324.800 -0.498
202512 1.230 324.054 1.253
202603 -1.250 330.213 -1.250

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-21.38 mean?
Curis (CRIS) has a E10 of $-21.38 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Curis and its competitors.
Is Curis' E10 too high?
Curis' current E10 is $-21.38. Overall, Curis has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Curis' E10 compare to CALC and ICU?
Curis' E10 of $-21.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Curis and its competitors. Curis's current E10 is $-21.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (CRIS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.04, compared to a current price of $0.31 — trading 69.8% below its estimated fair value. The current E10 is $-21.38. Curis' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Curis (CRIS), the current E10 is $-21.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Curis (CRIS) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be undervalued. The current stock price of $0.31 is trading 69.8% below its estimated GF Value™ of $1.04. GuruFocus considers Curis to be Possible Value Trap.

Key valuation signals for CRIS:

  • E10: $-21.38
  • GF Value™: $1.04 vs. price of $0.31 (69.8% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the CRIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CUS0:Germany
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
54GF Score

Get the complete analysis for CRIS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$1.04
GF Value